BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11237380)

  • 1. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
    Thirion P; Piedbois P; Buyse M; O'Dwyer PJ; Cunningham D; Man A; Greco FA; Colucci G; Köhne CH; Di Constanzo F; Piga A; Palmeri S; Dufour P; Cassano A; Pajkos G; Pensel RA; Aykan NF; Marsh J; Seymour MT;
    Br J Cancer; 2001 Mar; 84(5):611-20. PubMed ID: 11237380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
    J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
    J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Makower D; Wadler S
    Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.
    J Clin Oncol; 1994 May; 12(5):960-9. PubMed ID: 8164048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
    Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
    Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
    Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
    J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
    Pilati P; Mammano E; Mocellin S; Tessari E; Lise M; Nitti D
    Anticancer Res; 2009 Oct; 29(10):4139-44. PubMed ID: 19846962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
    Jodrell DI; Stewart M; Aird R; Knowles G; Bowman A; Wall L; McLean C
    Br J Cancer; 2001 Mar; 84(5):600-3. PubMed ID: 11237378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Glimelius B; Dahl O; Cedermark B; Jakobsen A; Bentzen SM; Starkhammar H; Grönberg H; Hultborn R; Albertsson M; Påhlman L; Tveit KM;
    Acta Oncol; 2005; 44(8):904-12. PubMed ID: 16332600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
    Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
    J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2 treatment in colorectal cancer: current results and future prospects.
    Heys SD; Deehan DJ; Eremin O
    Eur J Surg Oncol; 1994 Dec; 20(6):622-9. PubMed ID: 7995410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the relationship between response to treatment and survival time.
    Buyse M; Piedbois P
    Stat Med; 1996 Dec; 15(24):2797-812. PubMed ID: 8981687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.
    Buyse M; Thirion P; Carlson RW; Burzykowski T; Molenberghs G; Piedbois P
    Lancet; 2000 Jul; 356(9227):373-8. PubMed ID: 10972369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.